论文信息 - Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).

Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).

9537Background: Avelumab is a human anti–PD-L1 IgG1 antibody that showed a favorable efficacy and toxicity profile in pts with mMCC and progressive disease (PD) on or after chemotherapy (CT) in the...